AxoGen (AXGN) Stock Price, News & Analysis

-0.10 (-1.43%)
(As of 04/24/2024 ET)
Today's Range
50-Day Range
52-Week Range
120,303 shs
Average Volume
409,900 shs
Market Capitalization
$300.14 million
P/E Ratio
Dividend Yield
Price Target

AxoGen MarketRank™ Stock Analysis

Analyst Rating
3.00 Rating Score
55.3% Upside
$10.67 Price Target
Short Interest
4.26% of Float Sold Short
Dividend Strength
News Sentiment
Insider Trading
Selling Shares
$928,054 Sold Last Quarter
Proj. Earnings Growth
From ($0.46) to ($0.22) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.96 out of 5 stars

Medical Sector

464th out of 909 stocks

Electromedical Equipment Industry

8th out of 18 stocks

AXGN stock logo

About AxoGen Stock (NASDAQ:AXGN)

AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.

AXGN Stock Price History

AXGN Stock News Headlines

Biden replacement revealed?
A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.
Biden replacement revealed?
A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.
AxoGen Full Year 2023 Earnings: Beats Expectations
Axogen Inc (AXGN) Earnings Dates & Reports
AxoGen Q4 2023 Earnings Preview
American Well Corporation (AMWL)
Axogen Stock (NASDAQ:AXGN), Short Interest Report
AXGN Mar 2024 12.500 call
3 Best Stocks to Buy for Remarkable Earnings Acceleration
See More Headlines
Receive AXGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AxoGen and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Confirmed)
Fiscal Year End

Industry, Sector and Symbol

Electromedical equipment
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
3 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$159.01 million
Book Value
$2.22 per share


Free Float
Market Cap
$301.01 million
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Ms. Karen ZaderejMs. Karen Zaderej (Age 62)
    Chairman, President & CEO
    Comp: $852.18k
  • Mr. Michael Donovan (Age 59)
    Vice President of Operations
    Comp: $406.02k
  • Mr. Angelo G. Scopelianos Ph.D. (Age 68)
    Chief Research & Development Officer
    Comp: $540.91k
  • Mr. Nir Naor C.F.A. (Age 49)
    CPA, L.L.M., M.B.A., Chief Financial Officer
  • Mr. Harold D. Tamayo
    Vice President of Finance & Investor Relations
  • Mr. Marc A. Began (Age 56)
    Executive VP, General Counsel & Chief Compliance Officer
  • Ms. Doris Quackenbush
    Vice President of Sales
  • Mr. Jens Schroeder Kemp
    Chief Marketing Officer
  • Mr. Erick DeVinney (Age 48)
    Chief Innovation Officer
  • Dr. Ivica Ducic M.D.
    Ph.D., Chief Medical Officer

AXGN Stock Analysis - Frequently Asked Questions

Should I buy or sell AxoGen stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AxoGen in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AXGN shares.
View AXGN analyst ratings
or view top-rated stocks.

What is AxoGen's stock price target for 2024?

3 Wall Street analysts have issued 1-year price objectives for AxoGen's stock. Their AXGN share price targets range from $9.00 to $12.00. On average, they expect the company's stock price to reach $10.67 in the next twelve months. This suggests a possible upside of 55.3% from the stock's current price.
View analysts price targets for AXGN
or view top-rated stocks among Wall Street analysts.

How have AXGN shares performed in 2024?

AxoGen's stock was trading at $6.83 on January 1st, 2024. Since then, AXGN stock has increased by 0.6% and is now trading at $6.87.
View the best growth stocks for 2024 here

When is AxoGen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our AXGN earnings forecast

How can I listen to AxoGen's earnings call?

AxoGen will be holding an earnings conference call on Thursday, May 2nd at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were AxoGen's earnings last quarter?

AxoGen, Inc. (NASDAQ:AXGN) posted its quarterly earnings results on Tuesday, March, 5th. The medical equipment provider reported ($0.09) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.20) by $0.11. The medical equipment provider earned $42.92 million during the quarter, compared to analysts' expectations of $42.70 million. AxoGen had a negative net margin of 13.66% and a negative trailing twelve-month return on equity of 22.38%.

What ETF holds AxoGen's stock?

iShares Neuroscience and Healthcare ETF holds 2,930 shares of AXGN stock, representing 0.56% of its portfolio.

What guidance has AxoGen issued on next quarter's earnings?

AxoGen updated its FY 2024 earnings guidance on Wednesday, March, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $177.0 million-$181.0 million, compared to the consensus revenue estimate of $178.9 million.

What is Karen Zaderej's approval rating as AxoGen's CEO?

19 employees have rated AxoGen Chief Executive Officer Karen Zaderej on Karen Zaderej has an approval rating of 100% among the company's employees. This puts Karen Zaderej in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 83.0% of employees surveyed would recommend working at AxoGen to a friend.

What other stocks do shareholders of AxoGen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AxoGen investors own include Advanced Micro Devices (AMD), Bank of America (BAC), Intelsat (I), Intel (INTC), Micron Technology (MU), Xilinx (XLNX), Corbus Pharmaceuticals (CRBP), Exelixis (EXEL), NVIDIA (NVDA) and Fossil Group (FOSL).

Who are AxoGen's major shareholders?

AxoGen's stock is owned by a variety of institutional and retail investors. Top institutional investors include Rice Hall James & Associates LLC (0.35%). Insiders that own company stock include Amy Mcbride Wendell, Erick Wayne Devinney, Gregory Gene Freitag, Guido J Neels, Karen L Zaderej, Maria D Martinez, Michael Patrick Donovan, Peter J Mariani and William P Mr Burke.
View institutional ownership trends

How do I buy shares of AxoGen?

Shares of AXGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AXGN) was last updated on 4/24/2024 by Staff

From Our Partners